Quell Therapeutics to Present at Upcoming Investor Conferences in 2022
London, UK and Boston, MA, USA – November 22, 2022 – Quell Therapeutics Ltd (“Quell”), a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate…...
Read MoreQuell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer
Adds significant clinical, translational science and immunology expertise to leadership team as Quell prepares to advance QEL-001 into its first clinical trial and progresses its CAR-Treg cell therapy pipeline programs in Auto-Immunity and Neuro-Inflammation London, UK – November 21, 2022…...
Read MoreQuell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform
Collaboration combines Quell’s pioneering autologous multi-modular Treg cell therapy platform and Cellistic™’s expertise in iPSC cell therapy platform development and scale-upAims to accelerate the development of a next-generation allogeneic Treg platform that could open significant opportunities for Quell’s creation of…...
Read MoreQuell Therapeutics Announces Presentation at Oppenheimer’s 32nd Annual Healthcare Conference
London, UK and Boston, MA, USA – March 10, 2022 – Quell Therapeutics Ltd (“Quell”), a world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...
Read MoreQuell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
LONDON, UK and BOSTON, MA – January 6, 2022 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...
Read MoreQuell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focused investors - Proceeds to be used…...
Read MoreQuell Therapeutics Announces Participation in Upcoming Investor Conferences
London, UK and Boston, MA – November 22, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...
Read MoreQuell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy
First clinical trial will investigate QEL-001 as a novel treatment to prevent organ rejection in liver transplant patients and eliminate the need for lifelong systemic immunosuppression London, UK and Boston, MA, USA – October 27, 2021 – Quell Therapeutics Ltd (“Quell”),…...
Read MoreQuell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Technology to Enhance the Safety, Stability and Efficacy of Engineered Treg Therapies
Quell’s phenotype lock technology is a core element of its multi-modular engineered Treg platformLocks Treg cells in a potently suppressive phenotype and prevents switch to potentially pathogenic effector phenotypesPreclinical data presented at the European Society of Gene & Cell Therapy…...
Read More